Biome Australia (BIO) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
13 Feb, 2026Opening remarks and agenda
Meeting opened with confirmation of quorum and valid proxies representing 50,664,848 voting shares.
Voting conducted by poll, with each shareholder entitled to one vote per share held.
Notice of meeting taken as read, and agenda included financial statements, director and auditor reports, and several resolutions.
Financial performance review
FY24 sales reached AUD 13 million, up 80% year-on-year, with Q1 FY25 sales at AUD 4.25 million and adjusted EBITDA of AUD 122,000.
Gross margin maintained above 60%, increasing from 54% at IPO to 61%.
Cash at bank as of September 30 was AUD 2.67 million.
Same store sales in pharmacy for Q1 up 68% year-on-year, indicating strong organic growth.
Board and executive committee updates
Ms. Dominique Fisher re-elected as director by ordinary resolution.
Board and executive team commended for managing rapid growth and maintaining operational efficiency.
Latest events from Biome Australia
- Record revenue and profit growth, margin expansion, and clinical strength drive global momentum.BIO
Status update5 Jun 2026 - First net profit, record sales, and expanded distribution highlight strong H1 FY25.BIO
H1 20251 Jun 2026 - Sales revenue up 80% to $13.01m, gross margin over 60%, and positive EBITDA in H2 FY24.BIO
H2 20241 Jun 2026 - Achieved first net profit and 41.6% revenue growth, with strong global expansion and innovation.BIO
H2 20251 Jun 2026 - Record revenue and profit growth, strong margins, and expanding international presence.BIO
H1 20261 Jun 2026 - Q3 FY26 saw record probiotic sales, strong cash position, and continued growth across all segments.BIO
Q3 2026 TU27 Apr 2026 - Record sales and EBITDA growth, strong cash flow, and robust margins drive continued expansion.BIO
Q2 2026 TU26 Jan 2026 - Sales surged 41%, net profit achieved, and all key resolutions passed amid global expansion.BIO
AGM 202526 Nov 2025 - Record FY 2025 revenue and rapid growth set strong momentum for Vision 2027 targets.BIO
Investor Update16 Nov 2025